120 related articles for article (PubMed ID: 23233226)
1. Computational analysis of deleterious missense mutations in aspartoacylase that cause Canavan's disease.
Sreevishnupriya K; Chandrasekaran P; Senthilkumar A; Sethumadhavan R; Shanthi V; Daisy P; Nisha J; Ramanathan K; Rajasekaran R
Sci China Life Sci; 2012 Dec; 55(12):1109-19. PubMed ID: 23233226
[TBL] [Abstract][Full Text] [Related]
2. Exploring the cause of drug resistance by the detrimental missense mutations in KIT receptor: computational approach.
Rajasekaran R; Sethumadhavan R
Amino Acids; 2010 Aug; 39(3):651-60. PubMed ID: 20140688
[TBL] [Abstract][Full Text] [Related]
3. Homozygosity for mutation G212A of the gene for aspartoacylase is associated with atypical form of Canavan's disease.
Velinov M; Zellers N; Styles J; Wisniewski K
Clin Genet; 2008 Mar; 73(3):288-9. PubMed ID: 18070137
[No Abstract] [Full Text] [Related]
4. Docking, molecular dynamics and free energy studies on aspartoacylase mutations involved in Canavan disease.
Kocak A; Yildiz M
J Mol Graph Model; 2017 Jun; 74():44-53. PubMed ID: 28349879
[TBL] [Abstract][Full Text] [Related]
5. Aspartoacylase catalytic deficiency as the cause of Canavan disease: a structural perspective.
Wijayasinghe YS; Pavlovsky AG; Viola RE
Biochemistry; 2014 Aug; 53(30):4970-8. PubMed ID: 25003821
[TBL] [Abstract][Full Text] [Related]
6. Structure of aspartoacylase, the brain enzyme impaired in Canavan disease.
Bitto E; Bingman CA; Wesenberg GE; McCoy JG; Phillips GN
Proc Natl Acad Sci U S A; 2007 Jan; 104(2):456-61. PubMed ID: 17194761
[TBL] [Abstract][Full Text] [Related]
7. Novel mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
Unalp A; Altiok E; Uran N; Oztürk A; Yüksel S
J Trop Pediatr; 2008 Jun; 54(3):208-10. PubMed ID: 17999961
[TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of aspartoacylase: implications for Canavan disease.
Hershfield JR; Pattabiraman N; Madhavarao CN; Namboodiri MA
Brain Res; 2007 May; 1148():1-14. PubMed ID: 17391648
[TBL] [Abstract][Full Text] [Related]
9. New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion.
Di Pietro V; Cavallari U; Amorini AM; Lazzarino G; Longo S; Poggiani C; Cavalli P; Tavazzi B
Clin Biochem; 2013 Dec; 46(18):1902-4. PubMed ID: 24036223
[TBL] [Abstract][Full Text] [Related]
10. Mild-onset presentation of Canavan's disease associated with novel G212A point mutation in aspartoacylase gene.
Janson CG; Kolodny EH; Zeng BJ; Raghavan S; Pastores G; Torres P; Assadi M; McPhee S; Goldfarb O; Saslow B; Freese A; Wang DJ; Bilaniuk L; Shera D; Leone P
Ann Neurol; 2006 Feb; 59(2):428-31. PubMed ID: 16437572
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis of Canavan's disease: from human to mouse.
Surendran S; Matalon KM; Tyring SK; Matalon R
J Child Neurol; 2003 Sep; 18(9):604-10. PubMed ID: 14572138
[TBL] [Abstract][Full Text] [Related]
12. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease.
Kaul R; Gao GP; Balamurugan K; Matalon R
Nat Genet; 1993 Oct; 5(2):118-23. PubMed ID: 8252036
[TBL] [Abstract][Full Text] [Related]
13. Comparative computational assessment of the pathogenicity of mutations in the Aspartoacylase enzyme.
George Priya Doss C; Zayed H
Metab Brain Dis; 2017 Dec; 32(6):2105-2118. PubMed ID: 28879565
[TBL] [Abstract][Full Text] [Related]
14. Identification of the zinc binding ligands and the catalytic residue in human aspartoacylase, an enzyme involved in Canavan disease.
Herga S; Berrin JG; Perrier J; Puigserver A; Giardina T
FEBS Lett; 2006 Oct; 580(25):5899-904. PubMed ID: 17027983
[TBL] [Abstract][Full Text] [Related]
15. In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs.
Rajasekaran R; Sethumadhavan R
Appl Biochem Biotechnol; 2010 Mar; 160(6):1723-33. PubMed ID: 19455431
[TBL] [Abstract][Full Text] [Related]
16. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
Eke GH; Iscan A; Cece H; Calik M
Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636
[TBL] [Abstract][Full Text] [Related]
17. Two novel aspartoacylase gene (ASPA) missense mutations specific to Norwegian and Swedish patients with Canavan disease.
Olsen TR; Tranebjaerg L; Kvittingen EA; Hagenfeldt L; Møller C; Nilssen O
J Med Genet; 2002 Sep; 39(9):e55. PubMed ID: 12205125
[No Abstract] [Full Text] [Related]
18. Murine aspartoacylase: cloning, expression and comparison with the human enzyme.
Namboodiri MA; Corigliano-Murphy A; Jiang G; Rollag M; Provencio I
Brain Res Mol Brain Res; 2000 May; 77(2):285-9. PubMed ID: 10837925
[TBL] [Abstract][Full Text] [Related]
19. A benign polymorphism in the aspartoacylase gene may cause misinterpretation of Canavan gene testing.
Propheta O; Magal N; Shohat M; Eyal N; Navot N; Horowitz M
Eur J Hum Genet; 1998; 6(6):635-7. PubMed ID: 9887384
[TBL] [Abstract][Full Text] [Related]
20. Purification and preliminary characterization of brain aspartoacylase.
Moore RA; Le Coq J; Faehnle CR; Viola RE
Arch Biochem Biophys; 2003 May; 413(1):1-8. PubMed ID: 12706335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
